Proprio, the surgical technology company pioneering AI-powered surgical intelligence, announced a partnership with the Harms Study Group (HSG), a global network of distinguished surgeons dedicated to improving outcomes for children with spinal deformities. The new Proprio–HSG Research Collaborative will link real-time intraoperative data from Proprio's Paradigm platform with HSG's global outcomes registry, creating a powerful new foundation for research and data quality in spine deformity care.
By capturing objective intraoperative measurements during live surgery and connecting them to long-term outcomes data, the collaboration aims to improve the precision, completeness, and consistency of registry data across HSG's international network of hospitals. The integrated dataset will support new research into surgical optimization, outcomes prediction, and the economics of data-led care.
"For more than 30 years, the Harms Study Group has set the global standard for collaborative spine research," said Gabriel Jones, CEO of Proprio. "Their registry is one of the most important data assets in medicine. With the power of AI and computer vision, Paradigm can now build on those decades of learning, turning insight into a continuously learning system that measures, learns, and improves with every surgery."
The collaboration will be built on a registry integration using Proprio's API, automating intraoperative data collection while reducing manual documentation. Proprio and HSG investigators will also co-author multicenter research studies and publications, expanding the evidence base for AI-driven surgical intelligence.
"This technology allows us and the physicians we work with to objectively quantify what happens inside the operating room, something we've never had access to before," said Dr. Firoz Miyanji, Orthopedic Spine Surgeon at BC Children's Hospital and VP of Research for the Harms Study Group. "Working with innovative, mission-aligned companies in this new age of AI opens the door to entirely new research questions and, ultimately, better outcomes for our patients."
